Dr. Eric W Colegrove, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 673 Mdg, 5955 Zeamer Avenue, Jber, AK 99506 Phone: 907-580-0276 |
Dr. Raul Angeles Jr., OD Optometrist Medicare: May Accept Medicare Assignments Practice Location: 5800 Westover Ave, Jber, AK 99506 Phone: 907-978-1937 |
Dr. Gretchen D Ariz, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 5955 Zeamer Ave, 673d Mdg, Jber, AK 99506 Phone: 907-580-1150 Fax: 907-580-1152 |
Ronald M Kichura Od Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5953 Zeamer Ave, Jber, AK 99506 Phone: 907-580-1150 |
Latitude 61 Eyecare, Llc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 5800 Westover Ave, Jber, AK 99506 Phone: 907-753-7515 |
Dr. Matthew Sabo Ubedei, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 5955 Zeamer Avenue, 673 Mdg, Jber, AK 99506 Phone: 907-580-1035 Fax: 907-580-3203 |
Dr. Alex C Kwon, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 673 Amds 5955 Zeamer Ave, Jber, AK 99506 Phone: 907-580-1150 |
News Archive
Risk of Urinary Tract Infections after Prostate Biopsy Highest in Men with Prior Infections or Significant Comorbidities, Report Swedish Researchers in The Journal Of Urology®
Evidence overwhelmingly supports a link between cognitive decline and cerebrovascular diseases such as atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy. Not only do individuals with cerebrovascular diseases have a much higher incidence of cortical microinfarcts (mini-strokes), but post-mortem histological and in vivo radiological studies also find that the burden of microinfarcts is significantly greater among people with vascular cognitive impairment and dementia (VCID) than in age-matched, non-demented individuals.
Pathologists have reported encouraging results from a new technique to increase the accuracy of staging bladder cancer tumors that could reduce the need to remove bladders from some patients.
Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today announced it has received clearance by Health Canada to initiate its Phase II dose-sparing clinical trial for an H5N1 Avian Influenza VLP vaccine candidate ("H5N1 vaccine").
› Verified 4 days ago